home
about us
our story
FUNDING & GRANTS
OUR SCIENTIFIC CO-FOUNDERS
OUR MANAGEMENT
OUR BOARD
science
F prau.
in Iflammatory Bowel Diseases
F prau.
in Cancer
MANUFACTURING LIVE BIOThERAPEUTICS
pipeline
Overview
Patients
Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy
newsroom
PUBLICATIONS
contact
menu
about us
about us
Our story
funding & grants
Our Scientific Co-founders
Our mission
Our values
Our management
Our board
Talents
science
science
Exl01
Crohn's Disease
Faecalibacterium Prausnitzii
in Inflammatory Bowel Diseases
Faecalibacterium Prausnitzii
immuno-oncology
Faecalibacterium Prausnitzii
in Recurrent
Clostridium difficile
Infections
Tryptophan metabolism
Manufacturing Live Biotherapeutics
pipeline
pipeline
EXL01’s description & clinical trials
Patients
EXL01 in Crohn’s Disease
EXL01 in Cancer Immunotherapy
EXL01 in Immuno-Oncology
EXL01 in recurrent
Clostridium difficile
infections
EXL02
EXL03
Regulatory Expertise
Intellectual Property
newsroom
newsroom
Corporate Presentation
Publications
News
Upcoming Events
contact
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences
Back to news
Wilco
Sep 27, 2017
Exeliom Biosciences joins Wilco Incubator
Explore
Jul 31, 2024
First patient for Ex-Libris
Explore
#GastricCancer #Oncology #ClinicalTrials #ImmunOncology #EXL01
Jul 17, 2026
The BIG Phase 2 study (Gastric Cancer is moving forward!
Explore
contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
